Targeting NF-κB Signaling for Multiple Myeloma

Ada Hang-Heng Wong; Eun Myoung Shin; Vinay Tergaonkar; Wee-Joo Chng

doi:10.3390/cancers12082203

Targeting NF-κB Signaling for Multiple Myeloma

Cancers (Basel). 2020 Aug 6;12(8):2203. doi: 10.3390/cancers12082203.

Authors

Ada Hang-Heng Wong^{1

2}, Eun Myoung Shin¹, Vinay Tergaonkar^{1

3

4}, Wee-Joo Chng^{5

6

7}

Affiliations

¹ Laboratory of NF-κB Signaling, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.
² AW Medical Company Limited, Macau, China.
³ Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.
⁴ Department of Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia.
⁵ Cancer Science Institute of Singapore, Singapore 117599, Singapore.
⁶ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
⁷ Department of Hematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore 119074, Singapore.

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy in the world. Even though survival rates have significantly risen over the past years, MM remains incurable, and is also far from reaching the point of being managed as a chronic disease. This paper reviews the evolution of MM therapies, focusing on anti-MM drugs that target the molecular mechanisms of nuclear factor kappa B (NF-κB) signaling. We also provide our perspectives on contemporary research findings and insights for future drug development.

Keywords: NF-κB; biomarker-guided targeted therapy; multiple myeloma; precision medicine.

Publication types

Review